Section Arrow
STTK.NASDAQ
- Shattuck Labs
Quotes are at least 15-min delayed:2024/12/23 22:20 EST
Last
 1.1
-0.05 (-4.35%)
Day High 
1.18 
Prev. Close
1.15 
1-M High
1.38 
Volume 
125.38K 
Bid
1.1
Ask
1.18
Day Low
1.0774 
Open
1.18 
1-M Low
0.94 
Market Cap 
54.90M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.17 
20-SMA 1.15 
50-SMA 1.23 
52-W High 11.76 
52-W Low 0.94 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.53/-0.84
Enterprise Value
58.31M
Balance Sheet
Book Value Per Share
2.02
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.66M
Operating Revenue Per Share
0.02
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.4031-0.2085-34.09%-- 
RAPTRAPT Therapeutics1.74+0.9146+110.81%-- 
TRAWTraws Pharma Inc12.57+7.55+150.40%-- 
CEROCERo Therapeutics Holdings0.0505-0.0056-9.98%-- 
RXRXRecursion Pharmaceuticals6.99+0.96+15.92%-- 
Quotes are at least 15-min delayed:2024/12/23 22:20 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.